As of November 7, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of ADC Therapeutics SA. The largest reported stake is Bain Capital Life Sciences Opportunities IV, L.P.'s, at 9.99%. 13 filings are on record since August 14, 2025 (Schedule 13G, October 29, 2026).
Sell to companies like ADC Therapeutics SA? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Bain Capital Life Sciences Opportunities IV, L.P. · Sole voting: 0 · Shared voting: 14,825,625 · Sole dispositive: 0 · Shared dispositive: 14,825,625 · SCHEDULE 13G, 2026-10-29
- · Reporting person: Nantahala Capital Management, LLC · Sole voting: 0 · Shared voting: 12,326,184 · Sole dispositive: 0 · Shared dispositive: 12,326,184 · SCHEDULE 13G, 2026-08-14
- · Reporting person: BlackRock, Inc. · Sole voting: 6,765,332 · Shared voting: 0 · Sole dispositive: 6,857,815 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-27
- · Holder: Redmile Group, LLC · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: Redmile Group, LLC · Percent: 9.9% · SCHEDULE 13G/A
ADC Therapeutics SA has 13 Schedule 13D or 13G filings on record since 2025-08-14. 6 holders' latest filing reports 5% or more of common shares, par value chf 0.08 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Bain Capital Life Sciences Opportunities IV, L.P. | 9.99% | 14,825,625 | SCHEDULE 13G, 2026-10-29 | 2026-10-22 |
| Redmile Group, LLC | 9.9% | 12,717,487 | SCHEDULE 13G/A, 2026-04-24 | 2026-04-20 |
| Nantahala Capital Management, LLC | 9.69% | 12,326,184 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| TCG Crossover GP II, LLC | 9.2% | 11,390,175 | SCHEDULE 13G, 2026-02-17 | 2025-10-27 |
| Prosight Management, LP | 6.8% | 8,477,338 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| BlackRock, Inc. | 5.4% | 6,857,815 | SCHEDULE 13G, 2026-07-27 | 2026-06-30 |
| Oaktree Fund Administration, LLC | 4.14% | 4,673,441 | SCHEDULE 13G/A, 2025-11-05 | 2025-09-30 |
| Point72 Asset Management, L.P. | 4% | 5,014,617 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Orbimed Capital LLC | 2.6% | 3,230,797 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind ADC Therapeutics SA and the warning signs.
Free to see. No signup.
Keep reading
More on ADC Therapeutics SA and the records around it.
ADC Therapeutics SA elsewhere on the record
Companies that share a holder
- Bain Capital Life Sciences Opportunities IV, L.P. also filed stake reports on 1 other company: OLEMA PHARMACEUTICALS, INC. (May 2026)
- Oaktree Fund Administration, LLC also filed stake reports on 3 other companies: TORM plc (Jun 2026), ONITY GROUP INC. (Jan 2026)
- Prosight Management, LP also filed stake reports on 5 other companies: OnKure Therapeutics, Inc. (Aug 2026), MeiraGTx Holdings plc (Feb 2026), Janux Therapeutics, Inc. (Feb 2026)
Watch ADC Therapeutics SA
Get an email when ADC Therapeutics SA files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on ADC Therapeutics SA?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on ADC Therapeutics SA: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ADC Therapeutics SA covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Opportunities IV, L.P. | 0 | 14,825,625 | 0 | 14,825,625 | SCHEDULE 13G, 2026-10-29 |
| Nantahala Capital Management, LLC | 0 | 12,326,184 | 0 | 12,326,184 | SCHEDULE 13G, 2026-08-14 |
| Wilmot B. Harkey | 0 | 12,326,184 | 0 | 12,326,184 | SCHEDULE 13G, 2026-08-14 |
| Daniel Mack | 0 | 12,326,184 | 0 | 12,326,184 | SCHEDULE 13G, 2026-08-14 |
| BlackRock, Inc. | 6,765,332 | 0 | 6,857,815 | 0 | SCHEDULE 13G, 2026-07-27 |
The latest filing identifies ADC Therapeutics SA by CUSIP H0036K147 and gives its principal executive office as Route de la Corniche 3B, 1066 Epalinges, Switzerland (SCHEDULE 13G, 2026-10-29).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Redmile Group, LLC | 14% | SCHEDULE 13G/A |
| 2025-11-05 | Oaktree Fund Administration, LLC | 4.14% | SCHEDULE 13G/A |
| 2025-11-13 | Prosight Management, LP | 5.8% | SCHEDULE 13G/A |
| 2026-02-13 | Prosight Management, LP | 6.8% | SCHEDULE 13G/A |
| 2026-02-17 | Point72 Asset Management, L.P. | 4% | SCHEDULE 13G/A |
| 2026-02-17 | Orbimed Capital LLC | 2.6% | SCHEDULE 13G/A |
| 2026-02-17 | Redmile Group, LLC | 12.7% | SCHEDULE 13G/A |
| 2026-02-17 | TCG Crossover GP II, LLC | 9.2% | SCHEDULE 13G |
| 2026-04-06 | Redmile Group, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-04-24 | Redmile Group, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-07-27 | BlackRock, Inc. | 5.4% | SCHEDULE 13G |
| 2026-08-14 | Nantahala Capital Management, LLC | 9.69% | SCHEDULE 13G |
| 2026-10-29 | Bain Capital Life Sciences Opportunities IV, L.P. | 9.99% | SCHEDULE 13G |
Questions about who owns ADC Therapeutics SA
Who owns ADC Therapeutics SA?
On this page, 6 holders' latest ownership filings report 5% or more of ADC Therapeutics SA: Bain Capital Life Sciences Opportunities IV, L.P. (9.99%, Schedule 13G, filed 2026-10-29), Redmile Group, LLC (9.9%, Schedule 13G/A, filed 2026-04-24), Nantahala Capital Management, LLC (9.69%, Schedule 13G, filed 2026-08-14), TCG Crossover GP II, LLC (9.2%, Schedule 13G, filed 2026-02-17) and Prosight Management, LP (6.8%, Schedule 13G/A, filed 2026-02-13); 1 more is listed above.
Who are the largest shareholders of ADC Therapeutics SA?
By the share each holder's latest filing reports, the largest holders of ADC Therapeutics SA on this page are Bain Capital Life Sciences Opportunities IV, L.P. (9.99%), Redmile Group, LLC (9.9%) and Nantahala Capital Management, LLC (9.69%).
When did Bain Capital Life Sciences Opportunities IV, L.P. buy into ADC Therapeutics SA?
The filings give report dates, not purchase dates. The earliest filing from Bain Capital Life Sciences Opportunities IV, L.P. on this page is the Schedule 13G, filed 2026-10-29, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for ADC Therapeutics SA
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 2, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for ADC Therapeutics SA. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.